Client News

VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease

InflaRx Announces Participation in September Investor Conferences

Mallia Aesthetics Achieves Key Regulatory Steps for Novel sCD83-Derived Ingredient for Hair Growth

Nyxoah Reports Second Quarter Financial and Operating Results

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Formycon Confirms Full-Year Guidance Following Business Development in line with Plan – Working Capital Raised

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program with evenamide as Add-on Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

NewronNotes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea